Investing.com - Qualigen Therapeutics reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Qualigen Therapeutics announced earnings per share of $-0.100 on revenue of $1.44M. Analysts polled by Investing.com anticipated EPS of $-0.140 on revenue of $1.62M.
Qualigen Therapeutics shares are down 79% from the beginning of the year, still down 92.92% from its 52 week high of $3.12 set on November 23, 2021.
Qualigen Therapeutics shares gained 1.98% in intra-day trade following the report.
Qualigen Therapeutics follows other major Healthcare sector earnings this month
Qualigen Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar